Research and Markets has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016" report to their offering.
'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016'; Metastatic Adenocarcinoma of The Pancreas pipeline therapeutics constitutes close to 34 molecules. Out of which approximately 30 molecules are developed by Companies and remaining by the Universities/Institutes.
Metastatic Adenocarcinoma of The Pancreas Metastatic pancreatic adenocarcinoma is a type of cancer that originates in the pancreas, but then spreads to other areas of the body, such as liver, lungs and bones. Symptoms include weight loss, decreased appetite, jaundice (a yellow tinge to the skin and the whites of the eyes), dark urine and pale clay-colored stools. Individuals may also experience nausea, vomiting and general malaise. The predisposing factors include family history, smoking, chronic pancreatitis and diabetes. Treatment includes surgery, chemotherapy and radiation therapy.
The report 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 3, 15, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 4 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/kcwjr5/metastatic
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006300/en/Business Wire
Last updated on: 03/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.